Can we speed up drug Administration without affecting patient safety?

by | Aug 21, 2017 | Blog

Analyses have shown the US Food and Drug Administration gets drugs to the market faster than other major regulators but it is still too slow. Can approvals be achieved quicker without affecting patient safety?

Some companies took years to submit their applications. Ivabradine took 51 months but in contrast Rivaroxiban took only 4 months. Although analysing data and writing a trial report may be time consuming, reducing the time that companies take to submit their applications seems like an appropriate and worthwhile achievement.

Submitting applications by drug companies showed the most delay and therefore may provide the best opportunity to speed up approval. It may be possible to accelerate drug approvals in other ways, for instance by changing processes earlier in the development programme, before the end of the pivotal trials.

To accelerate FDA drug approvals may be a challenging task but there are areas where speed may arise. However, to accelerate FDA drug approvals by lowering standards may prove costly for patients and healthcare budgets.

Testimonials

Pharmacy Consulting has been performing consultancy work for Vygon for several years, during that time they have provided us with a very professional and efficient service. PCL helped Vygon obtain their original Wholesale Dealers Licence and have provided Responsible Person  (RP) support to our Quality Team ever since.  PCL guided us successfully through our MHRA inspection. More recently, Jackie delivered GDP update training sessions for me and my deputy when I started in my new role as Head … Read more
Testimonial from Vygon